PNC-27 — a peptide studied for selective cancer cell killing through membrane HDM-2 targeting.
PNC-27 is a 32-amino-acid chimeric peptide built from two functional pieces: a fragment of the p53 tumor suppressor protein (residues 12-26) that binds to HDM-2, fused to a short cell-penetrating leader sequence. The design emerged from a specific insight — that cancer cells, unlike healthy cells, often display HDM-2 on the outside of their plasma membrane, where it becomes a uniquely accessible target.
What makes PNC-27 distinctive among investigational anti-cancer peptides is its mechanism. Rather than interfering with cell signaling or DNA replication, it physically punches holes in cancer cell membranes. When PNC-27 finds membrane-bound HDM-2, the two molecules assemble into ring-shaped complexes that form transmembrane pores, causing the cell to spill its contents and die by necrosis. Because untransformed cells don't display HDM-2 on their surface, they're left untouched in the same experiments — a selectivity that has held up across more than a decade of laboratory work spanning solid tumors, leukemias, and patient-derived cancer cells.
1 vendor carries PNC-27.
Compare prices →The central finding behind PNC-27 research is that HDM-2 — a protein normally found inside cells, where it regulates p53 — gets externalized to the plasma membrane in cancer cells. This relocation appears to be a near-universal feature of transformed cells and is absent in their healthy counterparts.
Foundational work published in PNAS demonstrated this directly: significant levels of HDM-2 were detected in the membranes of multiple cancer cell lines but not in untransformed cells, and PNC-27 was shown to colocalize with this membrane-bound HDM-2 (1). The causal link was confirmed by transfecting normal MCF-10-2A breast cells with a membrane-localized HDM-2 construct — cells that were previously immune to PNC-27 became susceptible once they expressed HDM-2 on their surface (1).
Later structural work refined the picture. Conformational energy calculations and immuno-electron microscopy revealed that PNC-27 forms roughly 1:1 complexes with HDM-2, and these complexes assemble into ring-shaped pore structures visible in the membranes of treated cancer cells (2). Antibodies that block the p53-binding site on HDM-2 (residues 1-109) prevent PNC-27 from killing cancer cells, confirming that this specific interaction is what triggers pore formation (3). Dual-fluorescence labeling has shown that PNC-27 acts as an intact peptide rather than as fragments — the whole molecule is what assembles into pores (4).
PNC-27 has been tested across a wide range of cancer types, with consistent results: it kills the cancer cells and spares the normal ones.
In cervical cancer, PNC-27 showed cytotoxicity at an IC50 of 12.4 µM against HTB-35 squamous cervical cancer cells while leaving untransformed PCS-480 cervical cells unharmed — and the same selective HDM-2 membrane expression pattern held (5). In leukemia, three different acute myeloid leukemia cell lines (U937, OCI-AML3, HL-60) all showed high membrane HDM-2 and underwent rapid necrosis within four hours of PNC-27 treatment, with no effect on normal blood cells (6). Earlier work with K562 leukemia cells — which have no functional p53 at all — demonstrated that PNC-27 still killed nearly 100% of these cells, establishing that the mechanism works through a p53-independent pathway (7).
Perhaps most relevant for translation, PNC-27 has been tested against patient-derived ovarian cancer cells freshly isolated from two cystadenocarcinomas. The peptide was cytotoxic in a dose-dependent manner against these primary cancer cells and also against established chemotherapy-resistant ovarian cancer lines (8). A control peptide lacking the HDM-2-binding domain had no effect, reinforcing that the killing is mechanism-specific.
More recent work has uncovered a second mechanism that operates inside the cancer cell. After PNC-27 enters through its membrane interaction, some of it appears to make its way to mitochondria — the cell's energy-producing organelles — and disrupt them as well.
In pancreatic cancer cells (MIA-PaCa-2), PNC-27-treated cells lost the ability to retain mitotracker dye, indicating mitochondrial membrane disruption, while their lysosomes remained intact (2). Immuno-electron microscopy with gold-labeled anti-PNC-27 antibodies showed gold particles directly on the mitochondrial membranes, confirming the peptide's physical presence there. This dual mechanism — outer membrane pore formation through HDM-2 plus mitochondrial disruption — may explain why PNC-27 kills cancer cells so completely once it engages them.
Because PNC-27 targets cells based on a membrane feature rather than a cell-cycle stage, it complements conventional chemotherapy in interesting ways. Paclitaxel, a workhorse chemotherapy drug, kills cancer cells in the M phase of division but spares cells in other phases — those survivors then repopulate the tumor.
In ovarian cancer studies, paclitaxel-surviving cells were shown to upregulate MDM-2 (the human gene for HDM-2) on their surface, making them more susceptible to PNC-27, not less (9). The combination produced a synergistic effect — meaning the two drugs together did more than the sum of their individual effects — with a combination index below 1. In an intraperitoneal ovarian cancer model, adding PNC-27 to weekly paclitaxel significantly reduced tumor growth compared to paclitaxel alone (9).
PNC-27's HDM-2-binding domain has also been explored as a targeting ligand for diagnostic nanoparticles. PNC-27-conjugated iron oxide nanoparticles preferentially bound HDM-2-expressing cancer cells over normal cells, suggesting potential applications in early cancer imaging that piggyback on the same selectivity that makes the peptide cytotoxic (10).
PNC-27 has been studied almost exclusively in laboratory settings, and the safety picture in the published research is shaped by what's been measured: untransformed cells across many tissue types — breast, cervical, blood, fibroblast — consistently survive PNC-27 exposure that kills neighboring cancer cells (1, 5, 7). A control peptide lacking the HDM-2-binding domain shows no cytotoxic effects, indicating the killing is mechanism-specific rather than from generic membrane damage (8).
The body of PNC-27 evidence comes primarily from preclinical and laboratory work, with no published human clinical trial data so far. Long-term safety, pharmacokinetics, and tolerability in humans haven't been characterized. Selectivity that holds in cell culture may behave differently in a complete organism where HDM-2 expression patterns, immune responses, and off-target tissue exposure all come into play.
All information on this site is for research and educational purposes only. The compounds discussed are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.